#Australia #Sydney #Series B Funding #AI oncology #Lumonus

Lumonus Raises A$25 Million to Scale Global AI Oncology Workflows

Lumonus, a frontrunner in the realm of AI-driven radiation oncology solutions, has recently completed a significant Series B financing round, amassing A$25 million. This round was spearheaded by Aviron Investment Management and received continued backing from Oncology Ventures. This strategic investment marks a pivotal moment in Lumonus's journey as it seeks to expand its capabilities and bolster its presence in the oncology sector.

The funding underscores the increasing acceptance and integration of Lumonus's AI technology within leading healthcare institutions in the United States, Australia, and Europe. The Lumonus platform is streamlining vital oncology workflows, having already supported healthcare professionals in the planning and administration of more than 280,000 cancer treatments while automating over 75,000 treatment plans. These achievements highlight the platform's effectiveness in enhancing the efficiency and consistency of cancer care.

The leadership team at Lumonus, composed of seasoned professionals with over 100 years of cumulative experience in clinical, operational, and technical roles across cancer centers in multiple regions, lays a strong foundation for the company. This extensive expertise informs Lumonus's mission of creating solutions that empower healthcare teams to deliver high-quality and efficient treatment. Keith Hansen, the CEO of Lumonus, articulates the need for innovation in oncology, stating, "Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace."

As notable advancements occur in cancer treatment methodologies, Lumonus is committed to modernizing the underlying systems that facilitate these care processes. By leveraging an AI-native framework—which incorporates a comprehensive workflow approach—Lumonus is reimagining the landscape of oncology workflows in a way that directly addresses contemporary challenges faced by healthcare teams.

Reflecting on this milestone, Merrick Howes, Chairman of Lumonus, noted the hard work and collaboration of the entire team in partnership with clinicians around the world. He acknowledged the unique capabilities of Lumonus's AI-native platform in enhancing clinical quality and operational efficiency and expressed optimism about using the newly acquired capital to enhance product development and increase market presence in the United States.

Ben Freeberg, Managing Partner at Oncology Ventures, added, "The Lumonus team combines deep clinical expertise with world-class product execution and has already earned the trust of leading cancer centers internationally. We are proud to support Lumonus as they continue to deliver measurable impact and set the standard for the future of oncology workflows."

The Series B funding will primarily facilitate the expansion of Lumonus's clinical success and go-to-market teams in the U.S., advance core products like Lumonus AI Physician and Lumonus AI Dosimetry, and invest in pivotal clinical informatics capabilities. Furthermore, the company is set to deepen its collaborations with healthcare systems to harness real-world evidence, thereby enhancing quality, operational efficiency, and individualized patient care through data-driven approaches.

About Lumonus

Lumonus AI is at the forefront of revolutionizing cancer care through a digital oncology platform built on AI-native infrastructure. In partnership with leading cancer centers, Lumonus automates and coordinates crucial oncology workflows to improve treatment quality, speed, and lower administrative workloads—all while operating across the United States, Australia, and Europe.

About Aviron Investment Management

Aviron Investment Management is a private investment firm that specializes in healthcare and technology sectors, dedicated to identifying and supporting high-growth companies that leverage technology to tackle complex challenges in healthcare and life sciences. Aviron has partnered with Lumonus since its inception to guide its strategic direction and growth.

About Oncology Ventures

Oncology Ventures, based in New York, focuses exclusively on advancing innovation in cancer care by investing in early-stage companies that develop data infrastructure and AI-driven technologies. Their goal is to improve the accessibility and efficiency of oncology services worldwide. With extensive knowledge of the oncology sector, Oncology Ventures collaborates with visionary entrepreneurs to transform cancer diagnosis, treatment, and care delivery.

To find out more about Lumonus and their innovative solutions, visit www.lumonus.com.